Protagonist Therapeutics' midstage clinical trial has initiated dosing for its first patient to assess its injectable hepcidin mimetic peptide candidate PTG-300 as a treatment for patients with beta thalassemia. The study will evaluate PTG-300 in transfusion-dependent and non-transfusion-dependent patients, with preliminary data possibly available in the second half of 2019.
Dosing started for beta thalassemia candidate in midstage trial
Sign up for AABB SmartBrief
News about transfusion and cellular therapies
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.